150989-61-0

Usage

Molecular weight

279.36 g/mol

Chemical structure

1H-Azepine-1-carboxylic acid, 4-aminohexahydro-3-hydroxy-, phenylmethyl ester

Functional class

GABA agonist

Therapeutic uses

Insomnia, anxiety disorders, and alcohol withdrawal symptoms

Side effects

Drowsiness, dizziness, and impaired coordination

Status

Discontinued in some countries due to safety concerns.

Upstream product

• 150989-59-6 8-oxo-3-azabicyclo[5.1.0]octane-3-carboxylic acid benzyl ester 
• 150989-58-5 2,5,6,7-Tetrahydro-1H-azepine 
• 281219-33-8 4-azido-3-hydroxy-azepane-1-carboxylic acid benzyl ester 
• 281221-20-3 4-tert-butoxycarbonylamino-3-hydroxy-azepane-1-carboxylic acid benzyl ester 
• 150989-62-1 2,3,4,7-tetrahydro-azepine-1-carboxylic acid benzyl ester 
• 281219-32-7 allylpent-4-enylcarbamic acid benzyl ester 
• 5041-33-8 N-(Benzyloxycarbonyl)allylamine 
• 501-53-1 benzyl chloroformate 
• 3349-62-0 cyclohex-2-enone oxime 
• 930-68-7 cyclohexenone 
• 2228-79-7 1,5,6,7-Tetrahydro-2H-azepin-2-one 

Downstream Products

• 281219-34-9 4-((S)-2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepan-1-carboxylic acid benzyl ester 
• 281217-45-6 SB 357114 
• 281219-45-2 4(R,S)-((S)-1-{3(R,S)-hydroxy-1-[2-(3-pyridin-2-ylphenyl)ethanoyl]azepan-4-ylcarbamoyl}-3-methylbutyl)carbamic acid tert-butyl ester 
• 281219-31-6 ((S)-1-{1-[4(R,S)-((S)-2-benzyloxycarbonylamino-4-methylpentanoylamino)-3-(R,S)-hydroxyazepan-1-yl]-methanoyl}-3-methylbutyl)carbamic acid benzyl ester 
• 281214-55-9 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{(R)-3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-amide 
• 281217-40-1 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{(S)-3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-amide 
• 281219-64-5 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-3-methyl-butyl)-amide 
• 678982-30-4 benzyl 3-hydroxy-4-[(N-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucine)amino]azepane-1-carboxylate 
• 556063-40-2 [1-(3-hydroxy-azepan-4-ylcarbamoyl)-cyclohexyl]-carbamic acid tert-butyl ester 
• 1247884-57-6 benzyl 3-hydroxy-4-picolinamidoazepane-1-carboxylate 
• 281221-45-2 4-((S)-2-tert-Butoxycarbonylamino-3-cyclohexyl-proprionylamino)-3-hydroxy-azepane-1-carboxylic acid benzyl ester 
• 369593-26-0 Benzofuran-2-carboxylic acid {(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide 
• 369593-24-8 {(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-phenylethyl}carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR COMPOUNDS AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Q, X, Y, Z, R1, R7 and n are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modul

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, psychiatric disorders, neuromuscular disorders, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds provided herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Methods of treatment

The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin L in the treatment of diseases in which cathepsin L is implicated, especially treatment or prevention of rheumatoid arthritis; treatment or prevention of cancer metastasis; treatment or prevention of diseases requiring inhibition of tissue destruction by macrophage, particularly lung macrophage, such as asthma, chronic obstructive pulmonary disease (COPD), and emphysema; treatment or prevention of diseases requiring, for therapy, inhibition of positive selection of CD4+ T-cells by cortical thymic epithelial cells.

Cathepsin L inhibitors

The present invention provides methods which uses certain 4-amino-azepan-3-ones to inhibit cathepsin L. Consequently they are useful for preventing or treating diseases in which cathepsin L is implicated, such as rheumatoid arthritis or inhibition of posi

Protease inhibitors

The present invention provides C3-C6 1-amino-1-acyl cycloalkane-substituted 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K,

Protease inhibitors

The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

Protease inhibitors

The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma, and novel compounds for use therewith.

Protease inhibitors

This invention relates to the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof, which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition

Protease inhibitors

This invention relates to the compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvent thereof, which is an inhibitor of cysteine proteases, particularly cathespin K, and is useful in the treatment of diseases in which inhibition

Protease inhibitors

This invention relates to the compound of Formula (I): or a pharmaceutically acceptable salt, hydrate or solvate thereof, which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition